

# Patrick Sulzgruber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/69905/publications.pdf>

Version: 2024-02-01

80  
papers

1,067  
citations

361413

20  
h-index

477307

29  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2075  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	3.0	23
2	BLS courses for refugees are feasible and induce commitment towards lay rescuer resuscitation. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13644.	3.4	8
3	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	3.0	4
4	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 497-504.	2.6	8
5	Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, E1-E2.	3.0	0
6	The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	3
7	The Prognostic Potential of Growth Differentiation Factor-15 on Bleeding Events and Patient Outcome after Cardiac Surgeryâ€”A Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 703-714.	3.4	3
8	Very long-term survivors of in-hospital and out-of-hospital cardiac arrest show considerable impairment of daily life. <i>Resuscitation</i> , 2022, 173, 192-200.	3.0	5
9	Arterial stiffness in acute coronary syndrome as a potential triage tool: a prospective observational study. <i>Minerva Medica</i> , 2022, , .	0.9	0
10	Critical care during a pandemic â€”Are we prepared for the ethical dilemma?. <i>Journal of Critical Care</i> , 2022, 68, 174-175.	2.2	0
11	The Feasibility of Ultra-Sensitive Phonocardiography in Acute Chest Pain Patients of a Tertiary Care Emergency Department (ScorED Feasibility Study). <i>Journal of Personalized Medicine</i> , 2022, 12, 631.	2.5	1
12	The impact of left atrial mechanics on adverse events and clinical outcome after cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	1
13	Relationship of diabetes, heart failure, and Nâ€™terminal proâ€™Bâ€™type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. <i>ESC Heart Failure</i> , 2022, , .	3.1	2
14	The need for standardized echocardiographic work-up prior extracorporeal membrane oxygenation support in cardiogenic shock. <i>Oxford Medical Case Reports</i> , 2022, 2022, .	0.4	0
15	Long-term prognosis of <i>de novo</i> atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 189-195.	3.0	11
16	Changing paradigms in antiplatelet therapy after coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 206-208.	3.0	0
17	An increase in acute heart failure offsets the reduction in acute coronary syndrome during coronavirus disease 2019 (COVIDâ€™19) outbreak. <i>ESC Heart Failure</i> , 2021, 8, 782-783.	3.1	1
18	The impact of volume substitution on postâ€™operative atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13456.	3.4	8

#	ARTICLE	IF	CITATIONS
19	The Prognostic Potential of Atrial Natriuretic Peptide on the Development of Postoperative Atrial Fibrillation after Cardiac Surgery. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1523-1529.	3.4	3
20	Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 875-876.	2.6	0
21	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1161-1170.	2.6	4
22	Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: a focus on the net clinical benefit. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e83-e84.	3.0	1
23	The Prognostic Impact of Anti-thrombotic Treatment Strategies After Biological Aortic Valve Replacement. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	2.6	0
24	Ethical considerations during critical care from an age-specific perspective. <i>Resuscitation</i> , 2021, 166, 39-40.	3.0	0
25	The impact of invasive respiratory support on the development of postoperative atrial fibrillation following cardiac surgery. <i>Journal of Clinical Anesthesia</i> , 2021, 72, 110309.	1.6	1
26	The impact of CD4+CD28null T lymphocytes on atrial fibrillation: a potential pathophysiological pathway. <i>Inflammation Research</i> , 2021, 70, 1011-1014.	4.0	6
27	Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1â€“a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. <i>European Heart Journal</i> , 2021, 42, 541-543.	2.2	6
28	The prognostic impact of left ventricular thrombus resolution after acute coronary syndrome and risk modulation via antithrombotic treatment strategies. <i>Clinical Cardiology</i> , 2021, 44, 1692.	1.8	6
29	The Age-Specific Impact of Cellular Immunity on Long-Term Outcome after Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1246-1254.	3.4	0
30	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	3.0	27
31	Response to: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 267-268.	3.0	0
32	Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2020, 303, 80-85.	1.7	21
33	Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 273-274.	3.0	1
34	The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.6	0
35	An Extended Duration of the Pre-Operative Hospitalization is Associated with an Increased Risk of Healthcare-Associated Infections after Cardiac Surgery. <i>Scientific Reports</i> , 2020, 10, 8006.	3.3	10
36	The impact of a high-quality basic life support police-based first responder system on outcome after out-of-hospital cardiac arrest. <i>PLoS ONE</i> , 2020, 15, e0233966.	2.5	18

#	ARTICLE	IF	CITATIONS
37	CD8+CD28null T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1182-1187.	3.4	13
38	The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	3.0	6
39	Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction. <i>European Journal of Internal Medicine</i> , 2019, 59, 84-90.	2.2	28
40	Cardiac arrest as an age-dependent prognosticator for long-term mortality after acute myocardial infarction: the potential impact of infarction size. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 153-160.	1.0	4
41	Time of out-of-hospital cardiac arrest is not associated with outcome in a metropolitan area: A multicenter cohort study. <i>Resuscitation</i> , 2019, 142, 61-68.	3.0	13
42	Critical appraisal of the AUGUSTUS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 187-188.	3.0	1
43	Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. <i>European Heart Journal</i> , 2019, 40, 3010-3012.	2.2	4
44	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	3.0	46
45	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 226-236.	3.0	31
46	Aortic stenosis is an independent predictor for outcome in patients with in-hospital cardiac arrest. <i>Resuscitation</i> , 2019, 137, 156-160.	3.0	4
47	Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation. <i>Heart</i> , 2019, 105, 482-488.	2.9	18
48	The "Pectoral-Gap Phenomenon" - A Hypothesis on Origin and Mechanism. <i>Sports Medicine</i> , 2018, 48, 1987-1988.	6.5	1
49	Changing paradigms in oral anticoagulation during cardioversion in Europe. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 2-3.	3.0	1
50	Public access defibrillation is insufficiently available in rural regions - "When layperson efforts meet a lack of device distribution. <i>Resuscitation</i> , 2018, 126, e4-e5.	3.0	7
51	Pharmacotherapy during cardiac arrest - "When evidence-based data failed to be implemented in clinical practice guidelines. <i>Resuscitation</i> , 2018, 127, e7-e8.	3.0	1
52	Normal values for Doppler echocardiographic assessment of prosthetic valve function after transcatheter aortic valve replacement: a systematic review and meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 361-368.	1.2	10
53	The impact of airway strategy on the patient outcome after out-of-hospital cardiac arrest: A propensity score matched analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 423-431.	1.0	30
54	Oxygenation in post-resuscitation care - "how much is too much?". <i>Journal of Thoracic Disease</i> , 2018, 10, S2111-S2113.	1.4	3

#	ARTICLE	IF	CITATIONS
55	De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2018, 7, 474.	2.4	41
56	CD4+CD28null T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. <i>Scientific Reports</i> , 2018, 8, 9624.	3.3	19
57	Lipid profile and long-term outcome in premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13008.	3.4	18
58	Research update for articles published in <scp>EJCI</scp> in 2016. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13016.	3.4	0
59	Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2018, 23, 573-581.	3.9	22
60	Gender and age-specific aspects of awareness and knowledge in basic life support. <i>PLoS ONE</i> , 2018, 13, e0198918.	2.5	48
61	Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. <i>Journal of Clinical Lipidology</i> , 2017, 11, 178-184.	1.5	19
62	Advanced life support in pediatric out-of-hospital cardiac arrest—a two-year review and critical appraisal of quality of care and clinical outcome in a European metropolitan area. <i>Resuscitation</i> , 2017, 114, e21-e22.	3.0	0
63	Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 268-277.	4.1	37
64	Improvements in the quality of advanced life support and patient outcome after implementation of a standardized real-life post-resuscitation feedback system. <i>Resuscitation</i> , 2017, 120, 38-44.	3.0	17
65	Long-term outcome and risk prediction in patients suffering acute myocardial infarction complicated by post-infarction cardiac rupture. <i>International Journal of Cardiology</i> , 2017, 227, 399-403.	1.7	28
66	Age-specific prognostication after out-of-hospital cardiac arrest — The ethical dilemma between “life-sustaining treatment” and “the right to die” in the elderly. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 112-120.	1.0	44
67	Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction. <i>Thrombosis and Haemostasis</i> , 2017, 117, 471-478.	3.4	17
68	The impact of CD4+CD28null T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. <i>Thrombosis and Haemostasis</i> , 2017, 117, 349-356.	3.4	27
69	Prognostic relevance of circulating endothelial progenitor cells in patients with chronic heart failure. <i>Thrombosis and Haemostasis</i> , 2016, 116, 309-316.	3.4	21
70	Admission of out-of-hospital cardiac arrest victims to a high volume cardiac arrest center is linked to improved outcome. <i>Resuscitation</i> , 2016, 106, 42-48.	3.0	54
71	Impaired High-Density Lipoprotein Anti-Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	19
72	Gender-related differences in elderly patients with myocardial infarction in a European Centre. <i>European Journal of Clinical Investigation</i> , 2016, 46, 60-69.	3.4	7

#	ARTICLE	IF	CITATIONS
73	Editor's Choice-Progress in the chain of survival and its impact on outcomes of patients admitted to a specialized high-volume cardiac arrest center during the past two decades. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 3-12.	1.0	13
74	History of previous bleeding and C-reactive protein improve assessment of bleeding risk in elderly patients (≥80 years) with myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1085-1091.	3.4	9
75	Butyrylcholinesterase Predicts Cardiac Mortality in Young Patients with Acute Coronary Syndrome. <i>PLoS ONE</i> , 2015, 10, e0123948.	2.5	9
76	Mechanical chest compression does not seem to improve outcome after out-of hospital cardiac arrest. A single center observational trial. <i>Resuscitation</i> , 2015, 96, 220-225.	3.0	23
77	Von Willebrand Factor Improves Risk Prediction in Addition to N-Terminal Pro-B-type Natriuretic Peptide in Patients Referred to Coronary Angiography and Signs and Symptoms of Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 25-32.	3.9	25
78	The incidence of out-of-hospital cardiac arrest candidates for emergency department utilization of emergency extracorporeal life support: A one-year review. <i>Resuscitation</i> , 2015, 91, 131-136.	3.0	59
79	Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 1059-1067.	3.9	42
80	Survivors of cardiac arrest with good neurological outcome show considerable impairments of memory functioning. <i>Resuscitation</i> , 2015, 88, 120-125.	3.0	46